Medscape argues the race to crown the best drug risks crowding out the view of obesity as a disease that needs individualized, long-term care.
Recap by typeshit. Post by Medscape on X.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
2:06:18
A live Q&A from FitFlavorFun taking viewer questions on Zepbound, Ozempic, Wegovy, retatrutide and Korglutide.
People familiar with the matter say the plan under review includes more safeguards for patients than first expected. A policy step worth watching.
Loading…